Capricor Q1 2023 net loss $7.8M; HOPE-3 DMD trial interim analysis on track for Q4 2023

CAPRICOR THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.31 revenue$2,986,696

Net loss $7.8M ($0.31 per share) flat YoY; revenue $3.0M from Nippon Shinyaku deal vs zero prior year.
Cash, equivalents and marketables $45.2M; runway into Q4 2024, excludes milestone payments.
HOPE-3 Phase 3 for CAP-1002 in DMD: 13 active sites, targeting full enrollment by H2 2023, interim analysis Q4 2023.
24-month HOPE-2 open-label extension data planned for presentation in Q2 2023.
Received $12M upfront from Japan partner Nippon Shinyaku; potential milestones up to ~$89M plus revenue share.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CAPRICOR THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue approximately $3.0 million, net income approximately $7.8 million, or $0.31 per share, EPS $0.31 per share.

Period: first quarter ended March 31, 2023
Revenue: approximately $3.0 million
Net income: approximately $7.8 million, or $0.31 per share
EPS: $0.31 per share
Result: reported results

Exact text from the filing

U.S. Exclusive Commercialization and Distribution Agreement received from Nippon Shinyaku in the first quarter of 2022. Revenues for the first quarter of 2023 were approximately $3.0 million compared with zero for the first quarter of 2022. Operating expenses: Total operating expenses for the first quarter of 2023 were approximately $11.2 million compared with

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-009363

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.